09:40 AM EST - BioVaxys Technology Corp : Along with and SpayVac for Wildlife, Inc. jointly announce that SpayVac® recently completed set-up of its new research and production facility in Madison, Wisconsin to produce their long-lasting, single-dose veterinary contraceptive vaccines. SpayVac® uses a patented liposome-based antigen delivery platform technology, licensed from BioVaxys, which has demonstrated a robust and sustained immune response in several species. SpayVac single-dose vaccines will address the fertility-control needs in wildlife, agricultural production animals, and aquaculture markets. BioVaxys Technology Corp
shares C.BIOV are trading down one cent at $0.04.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=8402696043543476
